Cancer drug revenue substantially higher than R&D spending

"A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the United States market," Vinay Prasad, MD, MPH, hematologist-oncologist and assistant professor of medicine at the Oregon Health and Science Universit...

Full description

Saved in:
Bibliographic Details
Published inHEM/ONC today Vol. 18; no. 23; p. 77
Main Authors Tedesco, Alaina, Farinde, Abimbola
Format Journal Article
LanguageEnglish
Published Thorofare SLACK INCORPORATED 10.12.2017
Subjects
Cancer
Consumer Price Index
Costs
FDA approval
Opportunity costs
Pharmaceutical industry
R&D
Research & development
Research & development expenditures
Researchers
United States > US
Online AccessGet full text

Cover

More Information
Summary:"A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the United States market," Vinay Prasad, MD, MPH, hematologist-oncologist and assistant professor of medicine at the Oregon Health and Science University, and Sham Mailankody, MBBS, medical oncologist and hematologist at Memorial Sloan Kettering Cancer Center, wrote. In a related commentary, Merrill Goozner, MS, editor emeritus of Modern Healthcare, wrote that these findings offer a powerful perspective and an essential corrective on cancer drug development costs. "Policymakers can safely take steps to rein in drug prices without fear of jeopardizing innovation." - by Alaina Tedesco ? PERSPECTIVE The issue of pharmaceutical drug pricing has been at the forefront of a variety of discussions within medical communities, health care facilities and Abimbola Farinde amongst consumers for several years.
ISSN:1526-0488